Ascendia

25 Year BadgeDrug Development & Delivery Celebrates 25 Years!

For a quarter century, Drug Development & Delivery has connected innovators, scientists, and industry leaders while spotlighting the technologies and ideas shaping the future of the industry. We celebrate 25 years of advancing the conversation!

  MARKET NEWS

 

SCHOTT Pharma and Nemera Co-Develop Integrated 5.5 mL Syringe and Safety Platform to Advance At-Home Biologic Delivery
Lonza Capsugel Introduces Integrated Approach to Nitrosamine Risk Assessment
Eli Lilly Breaks Ground on $6.5B Houston API Facility to Scale Oral GLP-1 and Genetic Medicines
AI Algorithm Guides Modified-Release Tablet Design in Ongoing Clinical Study

  EXPERT CONTENT & RESOURCES

Modeling Polymor Interactions to Improve Amorphous Dispersion Design

Modeling Polymor Interactions to Improve Amorphous Dispersion Design

In this case study, OSDPredict™ narrowed formulation options early, focusing development on the most viable strategies which reduced experimental burden and conserved valuable materials.

The Last Mile of Digital Implementation: A Technical Framework for Turning Clinical Technology Adoption Into Measurable Value

The Last Mile of Digital Implementation: A Technical Framework for Turning Clinical Technology Adoption Into Measurable Value

As clinical trials become increasingly digitally enabled, organizations must look beyond successful technology deployment to determine whether new tools are delivering measurable value. This article presents a five-layer framework for evaluating technical fitness, workflow integration, adoption, data reliability, and operational outcomes to help translate clinical technology investments into better trial execution and evidence.

FROM ASSESSMENT TO SUSTAINABLE ACTION - Circular Economy Strategies & Practical Routes to Lower-Impact Medical Devices

FROM ASSESSMENT TO SUSTAINABLE ACTION - Circular Economy Strategies & Practical Routes to Lower-Impact Medical Devices

AstraZeneca and Novo Nordisk have both committed to science-based net-zero across their full value chains by 2045. However, decarbonizing manufacturing alone leaves most of the footprint untouched. Meeting these net-zero targets requires changes to the products themselves, the devices that deliver them, and the systems built around them, including the reprocessing and reuse networks. The route to a more sustainable device is not the same for every product, and the single biggest determinant of what is achievable is where a device sits in its product development lifecycle when sustainability is first considered.

  FEATURED EDITORIAL

  EXPERT INSIGHTS VIDEOS

Oral Peptide Drug Delivery: Overcoming Bioavailability & Formulation Challenges

Oral Peptide Drug Delivery: Overcoming Bioavailability & Formulation Challenges

  COMPANY PROFILE

Abzena

Abzena is the leading end-to-end CDMO + CRO for bioconjugates (ADCs, AOCs, RDCs), and complex biologics. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule.

Click here for more.

 

  WHITEPAPERS & WEBINARS

WHITEPAPER - Large-Scale LNP Process Conversions

WHITEPAPER - Large-Scale LNP Process Conversions

Large-Scale LNP Process Conversions: The many hurdles of LNP scale-up and what to consider

Lipid nanoparticle (LNP) formulation development begins on a small scale, often with homemade or benchtop setups, using syringe pumps and easily accessible micro-mixing systems. Once …

WEBINAR - Challenges of Sustained Release Drug Delivery Devices

WEBINAR - Challenges of Sustained Release Drug Delivery Devices

Sustained release drug delivery is rapidly expanding across respiratory, ophthalmic, transdermal, and implantable applications, but translating products from development to manufacturing remains both complex and costly. Programs can stall due to material–drug compatibility issues, inconsistent release profiles, tooling-related variability, and …

WHITEPAPER - Streamlined Product Development Leveraging Pharmaceutical Classification Models

WHITEPAPER - Streamlined Product Development Leveraging Pharmaceutical Classification Models

A technology agnostic approach based on a fundamental understanding of API properties, a well-defined yet flexible target product profile, and a mindset for scalability and commercial relevance leads to success in formulation development and drug product design.

In this whitepaper, …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 7 – Prefilled Syringes
October 14 – Injection Devices
October 21 – Transdermal/Topical Delivery
October 28 – Formulation Development

To advertise in a future eNewsletter contact:

John Kiesewetter jkiesewetter@drug-dev.com
Amy Nicklaus anicklaus@drug-dev.com

Submit eNewsletter content:

Cindy Dubin cdubin@drug-dev.com
Ralph Vitaro rvitaro@drug-dev.com